On January 07, 2025 ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, reported its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer, Jason Lettmann, will deliver a company overview presentation on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time (Press release, ALX Oncology, JAN 7, 2025, View Source [SID1234649457]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation is available by clicking the link and can also be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.